Encoded Therapeutics begins enrolling first in-human trials for ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome
2024 is proving to be a promising year for the advancement of targeted therapies for Dravet syndrome, including some newly enrolling clinical studies to investigate a novel genetic-based therapy from Encoded Therapeutics which we will discuss further in today’s blog post. Dravet syndrome is caused by mutations in one copy of the SCN1A gene, which […]